Scleroderma laboratory findings: Difference between revisions
No edit summary |
m (Categories) |
||
Line 9: | Line 9: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 13:12, 17 June 2016
Scleroderma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Scleroderma laboratory findings On the Web |
American Roentgen Ray Society Images of Scleroderma laboratory findings |
Risk calculators and risk factors for Scleroderma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anti-centromere and anti-scl70/anti-topoisomerase antibodies) and occasionally by biopsy. Of the antibodies, 90% have a detectable anti-nuclear antibody. Anti-centromere antibody is more common in the limited form (80-90%) than in the systemic form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more susceptible to the systemic form).[1]